1. SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors.
- Author
-
Zagouri F, Terpos E, Fiste O, Liontos M, Briasoulis A, Katsiana I, Skafida E, Markellos C, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, and Dimopoulos MA
- Subjects
- Antineoplastic Agents therapeutic use, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Female, Humans, SARS-CoV-2, Vaccination, Antibodies, Neutralizing blood, Antibodies, Viral blood, Breast Neoplasms drug therapy, COVID-19 prevention & control, COVID-19 Vaccines immunology
- Abstract
Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment., Competing Interests: Declaration of competing interest The authors report no conflict of interest., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF